Document Detail

Pityriasis lichenoides: pathophysiology, classification, and treatment.
MedLine Citation:
PMID:  17298104     Owner:  NLM     Status:  MEDLINE    
Pityriasis lichenoides (PL) is an uncommon, acquired spectrum of skin conditions that poses various challenges to patients as well as clinicians. It is a difficult and debatable disorder to diagnose, categorize, and treat. Besides these inherent obstacles, PL merits awareness because of its potential to progress to cutaneous lymphoma or an ulceronecrotic presentation, both of which carry a significant risk of mortality. The scope of PL presentations is delineated along a continuum of multiple variants including pityriasis lichenoides et varioliformis acuta (PLEVA), pityriasis lichenoides chronica (PLC), and febrile ulceronecrotic Mucha-Habermann disease (FUMHD). Classification of these presentations as separate subsets is debatable in view of their overlapping clinical, histopathologic, and etiologic features. PLEVA generally presents as an acute-to-subacute skin eruption of multiple, small, red papules that develops into polymorphic lesions and vacillates with periods of varying remissions as well as possible sequelae of hyper/hypopigmentation and varicella-like scars. PLC has a more gradual manifestation of very small red-to-brown flat maculopapules with mica-like scale; it also follows a relapsing course but with long periods of remission. FUMHD is an acute and severe generalized eruption of purpuric and ulceronecrotic plaques with associated systemic involvement and a mortality rate of up to 25%; hence, it should be approached as a dermatologic emergency.Histopathological evaluation of PL usually reveals dermal, wedge-shaped, lymphocytic infiltrate, epidermal spongiosis, parakeratosis, and variable necrosis of keratinocytes. PLC demonstrates more subtle histology whereas, at the other end of the spectrum, febrile ulceronecrotic FUMHD exhibits the most exaggerated histological features. The pathogenic mechanism behind PL is unclear although infectious or drug-related hypersensitivity reactions versus premycotic lymphoproliferative disorder are the mainstay theories. The foremost therapies for PLEVA and PLC are phototherapy, systemic antibacterials, and topical corticosteroids. Aggressive treatment with immunosuppressant and/or immunomodulating agents as well as intensive supportive care are recommended for FUMHD. We first describe a representative case of a 14-year-old boy with PLC who was successfully treated with narrow-band UVB. We then review the pathophysiology, classification, and treatment of PL.
Amor Khachemoune; Marianna L Blyumin
Related Documents :
18325514 - Endometrial osseous metaplasia: an evolving cause of secondary infertility.
17917804 - Diagnostic validity of sensory over-responsivity: a review of the literature and case r...
10592414 - Lipodermatosclerosis - report of three cases and review of the literature.
1861334 - Peripheral arterial occlusion in infants--a report of two cases treated conservatively.
11244534 - Isolated inverted papilloma of the sphenoid sinus.
11532564 - Objective pulsatile tinnitus caused by intrapetrous dissecting aneurysm.
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  American journal of clinical dermatology     Volume:  8     ISSN:  1175-0561     ISO Abbreviation:  Am J Clin Dermatol     Publication Date:  2007  
Date Detail:
Created Date:  2007-02-14     Completed Date:  2007-04-19     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  100895290     Medline TA:  Am J Clin Dermatol     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  29-36     Citation Subset:  IM    
Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenal Cortex Hormones / therapeutic use
Anti-Bacterial Agents / therapeutic use
Diagnosis, Differential
Phototherapy / methods
Pityriasis Lichenoides* / classification,  diagnosis,  physiopathology,  therapy
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Anti-Bacterial Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs.
Next Document:  Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, doub...